BACKGROUND: We studied the effect of an intracameral bevacizumab injection on the corneal endothelium and iris neovessels (INV). METHODS: Ten eyes were studied in 10 patients with an average age of 52.1 +/- 13.17 years. Patients underwent intracameral bevacizumab injections at a concentration of 1.25 mg/0.05 mL. Intraocular pressure, best-corrected visual acuity, gonioscopy, neovascular membrane extent, anterior segment photography, iris fluorescein angiography, pachymetry, and specular microscopy were recorded preoperatively and postoperatively. RESULTS: The minimum follow-up period was 4 months. INVs started to regress within the first 2 days after the injection and regressed completely by the end of the fourth week. Reduction in INV leakage started 1 week after injection, and resolved in 8 eyes (80%) by the end of the fourth week. Intraocular pressure dropped significantly from 17.8 +/- 4.8 mmHg to 16.6 +/- 2.8 mmHg over 4 weeks. The mean endothelial cell loss was 3.95% +/- 6.78%. CONCLUSIONS: An intracameral bevacizumab injection proved to be safe for corneal endothelial cells.
BACKGROUND: We studied the effect of an intracameral bevacizumab injection on the corneal endothelium and iris neovessels (INV). METHODS: Ten eyes were studied in 10 patients with an average age of 52.1 +/- 13.17 years. Patients underwent intracameral bevacizumab injections at a concentration of 1.25 mg/0.05 mL. Intraocular pressure, best-corrected visual acuity, gonioscopy, neovascular membrane extent, anterior segment photography, iris fluorescein angiography, pachymetry, and specular microscopy were recorded preoperatively and postoperatively. RESULTS: The minimum follow-up period was 4 months. INVs started to regress within the first 2 days after the injection and regressed completely by the end of the fourth week. Reduction in INV leakage started 1 week after injection, and resolved in 8 eyes (80%) by the end of the fourth week. Intraocular pressure dropped significantly from 17.8 +/- 4.8 mmHg to 16.6 +/- 2.8 mmHg over 4 weeks. The mean endothelial cell loss was 3.95% +/- 6.78%. CONCLUSIONS: An intracameral bevacizumab injection proved to be safe for corneal endothelial cells.
Authors: Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Andre Okanobo; Kraig S Bower; Denise S Ryan; Francisco Amparo; William Stevenson; Pedram Hamrah; Nambi Nallasamy; Reza Dana Journal: Am J Ophthalmol Date: 2012-09-08 Impact factor: 5.258
Authors: Alejandro Lichtinger; Sonia N Yeung; Peter Kim; Maoz D Amiran; Uri Elbaz; Allan R Slomovic Journal: Int Ophthalmol Date: 2013-05-31 Impact factor: 2.031